Manufacturing Daily Summary
Manufacturing Daily Summary: What Happened on November 16, 2026
ProBioGen gains expanded GMP authorization for Berlin facility
The updated certificate adds viral products and advanced therapy medicines to the facility’s existing protein-manufacturing services.
Today in brief
ProBioGen received expanded manufacturing authorization for its Berlin facility, adding viral products and advanced therapy medicines to its GMP services.1
Manufacturing
An updated GMP certificate allows ProBioGen’s Berlin facility to produce sterile biological drug substances and investigational medicines, including viral vectors and vaccines.1 The facility has capacity for up to 200 liters of drug substance.1